Pali Momi Medical Center

Background This study aimed to determine the demographic and clinical characteristics of pregnant women presenting with placenta previa and study the risk factors for the development of placenta previa, management strategies of associated complications, and maternal and perinatal outcomes. Methodology This prospective, observational study was conducted in the Department of Obstetrics and Gynaecology at Dr. S.N. Medical College, Umaid Hospital, Jodhpur, Rajasthan, India from May to October 2019. All patients with placenta previa were studied based on clinical presentation, management, and fetal and maternal outcomes. Results A total of 10,041 patients delivered during the study period. Of these, 61 were diagnosed with either minor placenta previa (placental edge within 2 cm, not covering the internal os) or major placenta previa (placental edge reaching or overlapping the internal os) for an incidence of 0.6%. The majority of the cases (65.57%) were in the age group of 20-29 years. Among the cases of placenta previa, 13.11% had previous cesarean sections, and 9.83% underwent previous dilatation and curettage (D & C)procedures. Moreover, 78.68% of the cases had ultrasound findings of the placenta partially or completely covering the os. Most patients were delivered by cesarean section (96.7%), and only 3.27% were delivered by vaginal delivery. Intensive care unit admission was required in 14.75% of the cases. The most common maternal complications observed were antepartum and postpartum hemorrhage, transfusion of blood and blood products, and long hospital stays. The preterm delivery rate was 62.30%, and 37.70% were term deliveries. Almost half of the babies (49.18%) were born with a birth weight of ≥2.5 kg, and 50.81% were in the low-birth-weight category. Apgar scores >7 at five minutes were observed in 85.3% of cases. Neonatal intensive care unit (NICU)admissions were 39.34%, and most babies recovered and shifted to the mother's side. The incidence of maternal mortality was 1.63%, and perinatal mortality was 9.83%. Conclusions The incidence of placenta previa was comparable to that reported in previous studies. Prevalence was more among younger women residing in rural areas who were unaware of regular antenatal check-ups. The main presenting symptom was painless vaginal bleeding, and ultrasonography was the most common diagnostic modality. Antepartum and postpartum hemorrhage was themost dreadful obstetric complications in cases of placenta previa, whichaffected maternal and fetal outcomes. Preterm and low birth weight were the main reason for NICU admissions. A team-based approach is required in the management of placenta previa cases.

We report a case of statin-associated necrotising autoimmune myopathy successfully treated with subcutaneous immunoglobulin therapy (SCIG) monotherapy without corticosteroids. This is a 51-year old female with seronegative rheumatoid arthritis, who had been on statins for several years, who developed proximal muscle weakness and elevated creatine kinase after resuming her statin post sleeve gastrectomy for weight loss. Our patient had a history of severe side effects to prednisone. She did not respond to mycophenolate, cyclophosphamide, and rituximab treatment. She had responded to partial treatment with intravenous immunoglobulin (IVIG) but had a severe headache after IVIG infusion. IVIG treatment was discontinued. We tried SCIG treatment, and she was able to tolerate the SCIG treatment with intermittent headaches that were less intense. After treatment with SCIG, creatine kinase levels decreased significantly, with an improvement of muscle strength. She continues to do well on SCIG treatment. To our knowledge, no other cases of statin-associated necrotising autoimmune myopathy treated with SCIG have been reported in the literature. More studies and reports are needed to confirm the utility and efficacy of SCIG in statin-associated necrotising autoimmune myopathy, as well as to provide information about dosing, tolerability, and durability of SCIG in the treatment of statin-associated necrotising autoimmune myopathy.

With current life expectancies exceeding 78 years on average, to be confronted with the discovery of a rare cancer often found in advanced stages is a startling devastation. Angiosarcoma of the intestine is a rare and aggressive tumor that is not often considered in the differential diagnosis of intestinal obstruction. Once found and accurately diagnosed, it is a bewildering race against time as its median survival time is 150 days from diagnosis. This case report details a rare small intestinal angiosarcoma with its host surpassing current epidemiological standards of survival time despite only being eligible for chemotherapy.